BCD-264 (daratumumab biosimilar)
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 06, 2024
DARVIVA: A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
(clinicaltrials.gov)
- P3 | N=252 | Recruiting | Sponsor: Biocad
Monotherapy • New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology
November 19, 2023
A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=146 | Completed | Sponsor: Biocad | Active, not recruiting ➔ Completed
Trial completion
August 03, 2023
A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=146 | Active, not recruiting | Sponsor: Biocad
New P1 trial
1 to 3
Of
3
Go to page
1